Dune Medical Devices to Present at the 2016 Canaccord Genuity Medical Technologies Forum

new-york-1745087_1280PRESS RELEASE

(November 16, 2016 – Paoli, PA and New York) Dune Medical Devices today announced that CEO Lori Chmura is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 17th at 2:40 p.m. EST  (Track 6) at the Westin Grand Central in New York, NY.

The first commercial product based on Dune Medical’s proprietary radio frequency (RF) spectroscopy technology is the MarginProbe, which received its U.S. FDA Premarket Approval in December 2012. It has been helping surgeons ensure clean margins in lumpectomy procedures since 2013 and recently exceeded use in 10,000 patients. According to multiple peer-reviewed studies, MarginProbe is shown to reduce re-excision rates in lumpectomy procedures by 50 – 79 percent.

Dune’s next product, which recently earned a 3 million grant from the EC 2020 Horizon program, will expand the company’s surgical oncology portfolio to include a soft tissue biopsy system with its first indication in breast tissue.

“We put unique clinically actionable information into the hands of surgeons while in the OR to help them make the best possible decisions for patient care,” Chmura says. “Improving the standard of care around cancer surgery is what we strive for each and  every day.”

The MarginProbe System

The MarginProbe System consists of three primary components — the Sensor, the Attachment Mechanism and the Algorithm — designed to provide both reliable performance and ease of use for surgeons within the operating room environment. The system utilizes RF Spectroscopy in a unique and sophisticated way to analyze tissue to identify both normal and malignant cells.

The Science – RF Spectroscopy for Margin Assessment

Cancerous cells are uniquely different from healthy cells and consequently, have very different electromagnetic properties. The bioelectric differences between these breast cancer cells and regular cells can be detected using RF spectroscopy.

Once detected, the electromagnetic “signature” of cancerous cells can be compared to thousands of other cell signatures using Dune’s proprietary algorithm. A binary result is then reported to the surgeon in real time to support a decision regarding the removal of additional tissue from the breast.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real-time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. Dune Medical Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.dunemedical.com .

Contact
Paul Snyder
Write2Market for Dune Medical Devices
paul@write2market.com
+1 (404) 414-4240